Sagimet Biosciences Inc (SGMT): Price/Earnings to Growth Multiple

Symbol and logo of brand Sagimet Biosciences Inc (SGMT)

Sagimet Biosciences (SGMT) is currently burning capital without stable revenue while remaining in the clinical trial stage. Historical P/E-to-growth dynamics confirm valuation volatility, where 0.00 reflects the most recent metric value. High authority among physicians is driven by the development of unique inhibitors for liver therapy, while management is successfully adapting the business structure for the future commercial launch of the drug.

SGMT sagimet.com Price/Earnings to Growth Multiple (02/21/2024 - 11/17/2026)

Analytical breakdowns for Sagimet Biosciences Inc. (SGMT)

- share price and consensus valuation forecast:
Fundamental company analysis:SGMT - Sagimet Biosciences Inc
Signature product of sagimet.com

For Sagimet Biosciences (SGMT), whose research is constrained by global logistics disruptions and the complexities of conducting international trials, this indicator for identifying undervalued growth companies compares the current P/E multiple with the earnings growth rate. The mathematical ratio of price to business expansion rates allows for the determination of the fair value of shares, where a value below one signals potential undervalued growth of the asset.

Competitors of Sagimet Biosciences

ASND (Ascendis) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio madrigalpharma.com MDGL|CORT - Price/Earnings to Growth Multiple|Rhythm Corp - PEG Multiple|Price to Earnings Adjusted for Growth Rate Akero Therapeutics Inc|MTSR (Metsera) - Price/Earnings to Growth Multiple|MLTX: Company Value to Earnings Growth Ratio|CRNX (Crinetics Corp) - PEG Multiple|PEG Multiple NewAmsterdam Pharma|PEG Multiple SLNO|Price/Earnings to Growth Ratio FOLD (Amicus Therapeutics Inc)|Price/Earnings to Growth Ratio 89bio.com ETNB|Agios Corp (AGIO) - Price to Earnings Adjusted for Growth Rate|GPCR - Price/Earnings to Growth Ratio|MDXG: Price/Earnings to Growth Ratio|RZLT: PEG Multiple|LXRX - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio MBX Corp|Price/Earnings to Growth Multiple Altimmune Corp (ALT)|Price/Earnings to Growth Ratio aardvarktherapeutics.com (AARD)|Price/Earnings to Growth Multiple BioAge Labs, Inc. BIOA|PEG Multiple BMEA (Biomea Fusion)|Price to Net Income Growth Ratio quincetx.com|GUTS - Price/Earnings to Growth Ratio|vTv Therapeutics, Inc. - Company Value to Earnings Growth Ratio|ATPC: PEG Multiple|Pluri Inc (PLUR) - PEG Multiple|Price/Earnings to Growth Ratio Synlogic, Inc.|Price to Earnings Adjusted for Growth Rate Lipocine LPCN|Price/Earnings to Growth Ratio Matinas BioPharma Holdings Inc. (MTNB)|Price/Earnings to Growth Multiple Spruce Biosciences SPRB|Galecto Corp - Price/Earnings to Growth Multiple|carmellrx.com - Price/Earnings to Growth Ratio|LUMO - Price/Earnings to Growth Ratio|ONVO: Price/Earnings to Growth Ratio|Radius Health (RDUS) - Price/Earnings to Growth Ratio